NCT05043571View on ClinicalTrials.gov

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions
Lymphoblastic Leukemia, Acute, ChildhoodLymphoblastic LeukemiaLymphoblastic Leukemia, Acute AdultLymphoblastic Leukemia in ChildrenCARCAR T-Cell-Related Encephalopathy SyndromeRefractory Leukemia
Interventions
BIOLOGICAL

CAR T-cell therapy

This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.

Trial Locations (1)

119228

RECRUITING

Allen Yeoh Eng Juh, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER